Indacaterol in chronic obstructive pulmonary disease: An update for clinicians

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 1, 2012, Pages 25-36

  Yorgancioglu, Arzu ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Chronic obstructive pulmonary disease; Indacaterol; Long acting beta agonist

Indexed keywords

CORTICOSTEROID; FLUTICASONE; FORMOTEROL; INDACATEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

BINDING AFFINITY; BRONCHODILATATION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COUGHING; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART INFARCTION; HUMAN; INFECTION; INFESTATION; INSPIRATORY CAPACITY; LIPOPHILICITY; MEDIASTINUM DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 84859011075     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622311426204     Document Type: Review

References (30)

1. Balint B. Watz H. Amos C. Owen R. Higgins M. Kramer B. (2010) Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 5: 311–318.
2. Barnes P.J. Pocock S.J. Magnussen H. Iqbal A. Kramer B. Higgins M. et al. (2010) Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 23: 165–171.
3. Battram C. Charlton S.J. Cuenoud B. Dowling M.R. Fairhurst R.A. Farr D. et al. (2006) In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)- 1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled b 2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317: 762–770.
4. Beeh K.M. Beier J. (2009) Indacaterol: a new once daily long-acting beta 2 adrenoceptor agonist. Core Evidence 4: 37–41.
5. Beeh K.M. Beier J. (2010) The short, the long, and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 27: 150–159.
6. Beeh K.M. Khindri S. Eeg M. Drollmann A.F. (2009) Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD. Eur Respir J 34(Suppl. 53): E4357.
7. Beier J. Chanez P. Martinot J.B. Schreurs A.J. Tkácová R. Bao W. et al. (2007) Safety, tolerability and efficacy of indacaterol, a novel once-daily beta (2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 20: 740–749.
8. Buhl R. Dunn L.J. Disdier C. Lassen C. Amos C. Henley M. et al. on behalf of the INTENSITY study investigators. (2011) Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J [ePub ahead of print].
9. Buhl R. Mahler D.A. Owen R. Lassen C. Kramer B. (2010) Indacaterol Provides Effective Bronchodilation in Patients with COPD Irrespective of Age. European Respiratory Society.
10. Cazzola M. Calzetta L. Gabriella Matera M. (2011) β2-adrenoceptor agonists:current and future direction. Br J Pharmacol 163: 4–17.
11. Cazzola M. Calzetta L. Matera M.G. (2008) Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155: 291–299.
12. Chapman K.R. Rennard S.I. Dogra A. Owen R. Lassen C. Kramer B. (2011) Long-term safety and efficacy of indacaterol, a novel long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest, DOI: 10.1378/chest.10-183010.1378/chest.10-1830.
13. Dahl R. Chung K.F. Buhl R. Magnussen H. Nonikov V. Jack D. et al. for the INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. (2010) Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA formoterol, in COPD. Thorax 65: 473–479.
14. Decramer M. Donohue J. Owen R. Lassen C. Kramer B. (2010) Indacaterol Provides Effective Bronchodilation in Patients with COPD Regardless of Concomitant ICS Use. European Respiratory Society.
15. Donohue J.F. Fogarty C. Lötvall J. Mahler D.A. Worth H. Yorgancioglu A. et al. for the INHANCE study investigators. (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182: 155–162.
16. Dunn L.J. Buhl R. Lassen C. Henley M. Kramer B. (2010) Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Chest 138: 719A.
17. Feldman G. Siler T. Prasad N. Jack D. Piggott S. Owen R. et al. INLIGHT 1 study group. (2010) Efficacy and safety of indacaterol 150 µg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 10: 11.
18. GOLD. (2010) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2010, available at: http://www.goldcopd.com/.
19. Jones P.W. Mahler D.A. Gale R. Owen R. Kramer B. (2011) Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 105: 892–899.
20. Korn S. Kerwin E. Atis S. Amos C. Owen R. Lassen C. for the INSIST study group. (2011) Indacaterol once-daily provides superior efficacy to salmeterol: a 12-week trial. Respir Med 105: 719–726.
21. Kornmann O. Dahl R. Centanni S. Dogra A. Owen R. Lassen C. et al. for the INLIGHT-2. Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients study investigators. (2011) Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37: 273–279.
22. La Force C. Aumann J. Parreño L.D. Iqbal A. Young D. Owen R. et al. on behalf of the INTEGRAL study investigators. (2011) Sustained 24-hour efficacy of once-daily indacaterol (300 µg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther 24: 162–168.
23. O'Donnell D.E. Casaburi R. Vincken W. Puente-Maestu L. Swales J. Lawrence D. et al. for the INABLE 1 study group. (2011) Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 105: 1030–1036.
24. Pontier S.M. Percherancier Y. Galandrin S. Breit A. Galés C. Bouvier M. et al. (2008) Cholesterol-dependent separation of the β2-adrenergic receptor from its partners determines signaling efficacy. Insight into nanoscale organization of signal transduction. J Biol Chem 283: 24659–24672.
25. Rennard S.I. Chapman K.R. Luthra A. Swales J. Lassen C. Owen R. et al. (2009) Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD). Chest 136: 4S–4f.
26. Roig J. Hernando R. Mora R. (2009) Indacaterol, a novel once daily inhaled β2-adrenoreceptor agonist. Open Respir Med J 3: 27–30.
27. Siler T. Williams J. Yegen U. Owen R. Lassen C. Kramer B. (2010) The effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med 181: A4430.
28. Vogelmeier C. Ramos-Barbon D. Jack D. Piggott S. Owen R. Mark Higgins M. et al. for the INTIME study investigators. (2010) Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 11: 135.
29. Worth H. Chung K.F. Felser J.M. Hu H. Rueegg P. (2011) Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 105: 571–579.
30. Yorgancıoğlu A. Mahler D. Iqbal A. Owen R. Higgins M. Kramer B. et al. (2009) Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J 34(Suppl. 53): 346S.